Efalizumab
From Wikipedia, the free encyclopedia
| Image:Efalizumab.png | |
|
Efalizumab
|
|
| Systematic (IUPAC) name | |
| Humanized anti-CD11a antibody | |
| Identifiers | |
| CAS number | 214745-43-3 |
| ATC code | L04AA21 |
| PubChem | ? |
| DrugBank | BTD00074 |
| Chemical data | |
| Formula | ? |
| Mol. weight | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Efalizumab (Raptiva®, Genentech) is a medication used to treat psoriasis. It is a recombinant humanized monoclonal antibody that binds to CD11a and acts as an immunosuppressant. It is administered once weekly by subcutaneous injection.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
| Immunosuppressants (L04) edit | ||
|---|---|---|
|
Abetimus, Adalimumab, Afelimomab , Anakinra, Alefacept, Antilymphocyte immunoglobulin (horse), Antithymocyte immunoglobulin (rabbit) , Azathioprine, Basiliximab, Ciclosporin, Daclizumab, Efalizumab, Etanercept, Everolimus, Gusperimus , Infliximab, Leflunomide, Methotrexate , Muromonab-CD3 , Mycophenolic acid, Natalizumab, Pimecrolimus, Tacrolimus, Thalidomide, Sirolimus |
||
